Interactions with Entry and Attachment Inhibitors Charts Revised March 2021

www.hiv-druginteractions.org

Interactions with Entry and Attachment Inhibitors Charts revised March 2021. Full information available at www.hiv-druginteractions.org Page 1 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ABT FTR IBA MVC ABT FTR IBA MVC Anaesthetics & Muscle Relaxants Antibacterials Alcuronium     Amikacin     Bupivacaine     Amoxicillin     Cisatracurium     Ampicillin     Desflurane     Azithromycin     Dexmedetomidine     Bedaquiline     Enflurane     Capreomycin     Ephedrine     Cefalexin             Etidocaine Cefazolin Halothane     Cefixime     Isoflurane     Cefotaxime     Ketamine     Ceftazidime     Minaxolone     Ceftriaxone     Nitrous oxide     Chloramphenicol     Propofol     distribution. Ciprofloxacin    

Rocuronium     for Clarithromycin     Sevoflurane     Clavulanic acid     Sufentanil     Clindamycin     Suxamethonium (succinylcholine)     Clofazimine     Tetracaine     Cloxacillin     Thiopental     Cycloserine     Tizanidine     Dapsone     Vecuronium     Delamanid     Analgesics Doxycycline     Alfentanil     Ertapenem     Aspirin     Erythromycin     Buprenorphine     Ethambutol     Celecoxib     Ethionamide     Codeine     Flucloxacillin     Dextropropoxyphene     Gentamicin     Diamorphine (diacetylmorphine)     Imipenem/Cilastatin     Diclofenac     Isoniazid     Dihydrocodeine     Kanamycin     Fentanyl     Levofloxacin     Hydrocodone     Linezolid     Hydromorphone     Meropenem     Ibuprofen     Metronidazole     Mefenamic acid     Moxifloxacin     Methadone     Nitrofurantoin     Morphine     Ofloxacin     Naproxen     Para-aminosalicylic acid     Nimesulide     Penicillins     Oxycodone     Piperacillin     Paracetamol (Acetaminophen)     Pyrazinamide     Pethidine (Meperidine)     Rifabutin     Piroxicam     Rifampicin     Tapentadol     Rifapentine     Tramadol     Rifaximin     Anthelmintics Spectinomycin     Albendazole     Streptomycin     Diethylcarbamazine     Sulfadiazine     Ivermectin     Tazobactam     Levamisole (Ergamisol)     Telithromycin     Mebendazole     Tetracyclines     Niclosamide     Tinidazole     Oxamniquine     Trimethoprim/Sulfamethoxazole     Praziquantel     Vancomycin     Pyrantel     Anti-coagulant, Anti-platelet and Fibrinolytic Suramin sodium     Acenocoumarol     Triclabendazole     Apixaban     Antiarrhythmics Argatroban     Amiodarone     Aspirin (anti-platelet)     Bepridil     Betrixaban     Digoxin     Clopidogrel     Disopyramide     Dabigatran     Dofetilide     Dalteparin     Flecainide     Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Dipyridamole     Lidocaine (Lignocaine)     Edoxaban     Mexiletine     Enoxaparin     Propafenone     Fondaparinux     Quinidine     Heparin     Phenprocoumon     Prasugrel     Rivaroxaban     Streptokinase     Ticagrelor     Warfarin    

Key to abbreviations Key to symbols ABT Albuvirtide (Aikening®) ⚫ These drugs should not be coadministered FTR Fostemsavir (Rukobia®)  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment IBA Ibalizumab-uiyk (Trogarzo®) is unlikely to be required MVC Maraviroc (Celsentri®, Selzentry®) ◆ No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. www.hiv-druginteractions.org

Interactions with Entry and Attachment Inhibitors Charts revised March 2021. Full information available at www.hiv-druginteractions.org Page 2 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ABT FTR IBA MVC ABT FTR IBA MVC Anticonvulsants Antifungals Carbamazepine     Amphotericin B     Clonazepam     Anidulafungin     Eslicarbazepine     Caspofungin     Ethosuximide     Fluconazole     Gabapentin     Flucytosine     Lacosamide     Griseofulvin     Lamotrigine     Itraconazole             Levetiracetam Ketoconazole Oxcarbazepine     Miconazole     Phenobarbital (Phenobarbitone)     Nystatin     Phenytoin     Posaconazole     Pregabalin     Terbinafine     Primidone     Voriconazole     Tiagabine     distribution. Antihistamines

Topiramate     for Astemizole     Valproate (Divalproex)     Cetirizine     Vigabatrin     Chlorphenamine     Zonisamide     Diphenhydramine     Antidepressants Fexofenadine     Agomelatine     Levocetirizine     Amitriptyline     Loratadine     Bupropion     Promethazine     Citalopram     Terfenadine     Clomipramine     Antimigraine Agents Desipramine     Almotriptan     Desvenlafaxine     Dihydroergotamine     Doxepin     Eletriptan     Duloxetine     Ergotamine     Escitalopram     Rizatriptan     Fluoxetine     Sumatriptan     Fluvoxamine     Zolmitriptan     Imipramine     Antiprotozoals Lithium     Amodiaquine     Maprotiline     Artemisinin     Mianserin     Atovaquone     Milnacipran     Benznidazole     Mirtazapine     Chloroquine     Nefazodone     Diloxanide     Nortriptyline     Eflornithine     Paroxetine     Halofantrine     Phenelzine     Hydroxychloroquine     Reboxetine     Lumefantrine     Sertraline     Mefloquine     Tranylcypromine     Meglumine antimoniate     Trazodone     Melarsoprol     Trimipramine     Miltefosine     Venlafaxine     Nifurtimox     Vortioxetine     Paromomycin     Anti-diabetics Pentamidine     Acarbose     Piperaquine     Alogliptin     Primaquine     Canagliflozin     Proguanil     Dapagliflozin     Pyrimethamine     Dulaglutide     Quinine     Empagliflozin     Sodium stibogluconate     Exenatide     Sulfadoxine     Glibenclamide (Glyburide)     Antipsychotics/Neuroleptics Gliclazide     Amisulpride     Glimepiride     Aripiprazole     Glipizide     Asenapine     Insulin     Chlorpromazine     Linagliptin     Clozapine     Liraglutide     Fluphenazine     Metformin     Haloperidol    

Nateglinide     Iloperidone     For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Pioglitazone     Levomepromazine     Repaglinide     Olanzapine     Rosiglitazone     Paliperidone     Saxagliptin     Perazine     Sitagliptin     Periciazine     Tolbutamide     Perphenazine     Vildagliptin     Pimozide     Pipotiazine     Quetiapine     Risperidone     Sulpiride     Thioridazine     Tiapride     Ziprasidone     Zotepine     Zuclopenthixol    

Key to abbreviations Key to symbols ABT Albuvirtide (Aikening®) ⚫ These drugs should not be coadministered FTR Fostemsavir (Rukobia®)  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment IBA Ibalizumab-uiyk (Trogarzo®) is unlikely to be required MVC Maraviroc (Celsentri®, Selzentry®) ◆ No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. www.hiv-druginteractions.org

Interactions with Entry and Attachment Inhibitors Charts revised March 2021. Full information available at www.hiv-druginteractions.org Page 3 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ABT FTR IBA MVC ABT FTR IBA MVC Antivirals Calcium Channel Blockers Aciclovir     Amlodipine     Adefovir     Diltiazem     Amantadine     Felodipine     Cidofovir     Nicardipine     Daclatasvir     Nifedipine     Elbasvir/Grazoprevir     Nisoldipine     Entecavir     Nitrendipine             Famciclovir Verapamil Foscarnet     Cancer Therapies Ganciclovir     Anastrozole     Glecaprevir/Pibrentasvir     Asparaginase     Ledipasvir/Sofosbuvir     Bevacizumab    

Ombitasvir/Paritaprevir/r     Bexarotene     distribution. Ombitasvir/Paritaprevir/r + Dasabuvir     Bleomycin    

Oseltamivir     for Bortezomib     Remdesivir     Brentuximab vedotin     Ribavirin     Capecitabine     Rimantadine     Carboplatin     Simeprevir     Cetuximab     Sofosbuvir     Chlorambucil     Sofosbuvir/Velpatasvir     Cisplatin     Sofosbuvir/Velpatasvir/Voxilaprevir     Cyclophosphamide     Telbivudine     Cytarabine     Tenofovir alafenamide (HBV)     Dacarbazine     Valaciclovir     Dactinomycin     Zanamivir     Dasatinib     Anxiolytics/Hypnotics/ Sedatives Daunorubicin     Alprazolam     Docetaxel     Bromazepam     Doxorubicin     Buspirone     Droloxifene     Chlordiazepoxide     Enzalutamide     Clobazam     Epirubicin     Clorazepate     Erlotinib     Diazepam     Estramustine     Estazolam     Etoposide     Flunitrazepam     Everolimus     Flurazepam     Exemestane     Hydroxyzine     Fludarabine     Lorazepam     Fluorouracil     Lormetazepam     Formestane     Midazolam (oral)     Gefitinib     Midazolam (parenteral)     Gemcitabine     Oxazepam     Ifosfamide     Temazepam     Imatinib     Triazolam     Irinotecan     Zaleplon     Lapatinib     Zolpidem     Lenalidomide     Zopiclone     Letrozole     Beta Blockers Mercaptopurine     Atenolol     Mesna     Bisoprolol     Methotrexate     Carvedilol     Mitoxantrone     Metoprolol     Nilotinib     Nebivolol     Oxaliplatin     Oxprenolol     Paclitaxel     Pindolol     Pazopanib     Propranolol     Polatuzumab vedotin     Timolol     Procarbazine     Bronchodilators Rituximab     Aclidinium bromide     Sorafenib     Aminophylline     Sunitinib     Formoterol     Tamoxifen     Glycopyrronium bromide     Temsirolimus     Indacaterol     Topotecan     Ipratropium bromide     Toremifene     Montelukast     Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Trastuzumab     Olodaterol     Trastuzumab emtansine     Roflumilast     Vinblastine     Salbutamol     Vincristine     Salmeterol     Vinorelbine     Theophylline     Vorinostat     Tiotropium bromide     Umeclidinium bromide     Vilanterol    

Key to abbreviations Key to symbols ABT Albuvirtide (Aikening®) ⚫ These drugs should not be coadministered FTR Fostemsavir (Rukobia®)  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment IBA Ibalizumab-uiyk (Trogarzo®) is unlikely to be required MVC Maraviroc (Celsentri®, Selzentry®) ◆ No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. www.hiv-druginteractions.org

Interactions with Entry and Attachment Inhibitors Charts revised March 2021. Full information available at www.hiv-druginteractions.org Page 4 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ABT FTR IBA MVC ABT FTR IBA MVC Contraceptives/HRT Herbals/Supplements/Vitamins (continued) Desogestrel (COC)     Hops (Humulus lupulus)     Desogestrel (POP)     Inula racemosa     Drospirenone (COC)     Iodine [alone]     Drospirenone (HRT)     Iodine [in multivitamins]     Dydrogesterone (HRT)     Iron supplements     Estradiol     Liquorice (Glycyrrhiza glabra)     Magnesium supplements     Ethinylestradiol     Malabar nut tree         Etonogestrel (implant) Menthol        Etonogestrel (vaginal ring)  Milk thistle (silymarin)     Gestodene (COC)     Multivitamins     Levonorgestrel (COC)     Nicotinamide [alone]     Levonorgestrel (emergency contraception)     Nicotinamide [in multivitamins]     Levonorgestrel (HRT)     Phytomenadione (vitamin K) [alone]     Levonorgestrel (implant)     distribution. Phytomenadione [in multivitamins]    

Levonorgestrel (IUD)     for Pyridoxine (vitamin B6) [alone]     Levonorgestrel (POP)     Pyridoxine [in multivitamins]     Medroxyprogesterone (depot injection)     Quercetin     Medroxyprogesterone (oral)     Red yeast rice     Norelgestromin (patch)     Retinol (vitamin A) [alone]     Retinol (vitamin A) [in multivitamins]     Norethisterone [Norethindrone] (COC)     Riboflavin (vitamin B2) [alone]     Norethisterone [Norethindrone] (HRT)     Riboflavin [in multivitamins]         Norethisterone [Norethindrone] (IM depot) Saw palmetto (Serenoa repens)     Norethisterone [Norethindrone] (POP)     Seville orange juice     Norgestimate (COC)     St John's Wort     Norgestrel (COC)     Thiamine (vitamin B1) [alone]     Norgestrel (HRT)     Thiamine [in multivitamins]     Ulipristal     Tocopherol (vitamin E) [alone]     Erectile Dysfunctional Agents Tocopherol (vitamin E) [in multivitamins]     Avanafil     Turmeric (Curcuma longa)     Sildenafil (Erectile Dysfunction)     Valerian     Tadalafil (Erectile Dysfunction)     Hypertension / Heart Failure Agents Vardenafil     Aliskiren     Gastrointestinal Agents Ambrisentan     Amiloride        Alosetron  Benazepril     Antacids     Bendroflumethiazide     Bisacodyl     Bosentan     Cimetidine     Candesartan     Cisapride     Captopril     Dexlansoprazole     Chlortalidone     Esomeprazole     Cilazapril     Famotidine     Clonidine     Lactulose     Dopamine     Lansoprazole     Doxazosin     Enalapril     Loperamide     Eplerenone         Mesalazine Epoprostenol     Omeprazole     Eprosartan     Pantoprazole     Fosinopril     Prucalopride     Furosemide     Rabeprazole     Hydralazine     Ranitidine     Hydrochlorothiazide     Senna     Iloprost     Gastrointestinal Agents (anti-emetics) Indapamide     Irbesartan     Aprepitant     Isosorbide dinitrate     Dolasetron     Ivabradine     Domperidone     Labetalol     Dronabinol     Lacidipine     Granisetron     Lercanidipine     Metoclopramide     Lisinopril     Ondansetron     Losartan     Prochlorperazine     Macitentan     Herbals/Supplements/Vitamins Methyldopa     African potato     Metolazone     Aloe vera     Moxonidine     Ascorbic Acid (vitamin C) [alone]     Olmesartan     Perindopril Ascorbic Acid [in multivitamins]        

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Prazosin     Calcium supplements     Quinapril     Cat’s claw (Uncaria tomentosa)     Ramipril     Colecalciferol (vitamin D3) [alone]     Ranolazine     Colecalciferol [in multivitamins]     Riociguat     Cubeb pepper (Piper cubeba)     Sacubitril     Cyanocobalamin [alone]     Selexipag     Cyanocobalamin [in multivitamins]     Sildenafil (PAH)     Echinacea     Sodium nitroprusside     Eucalyptus globulus     Spironolactone     Ferrous fumarate     Tadalafil (PAH)     Folic acid [alone]     Telmisartan     Folic acid [in multivitamins]     Terazosin     Garlic     Torasemide     Ginger (Zinigiber officinale)     Trandolapril     Ginkgo biloba     Treprostinil     Goldenseal root (Hydrastis canadensis)     Valsartan     Grapefruit juice     Xipamide     Guggulsterone    

Key to abbreviations Key to symbols ABT Albuvirtide (Aikening®) ⚫ These drugs should not be coadministered FTR Fostemsavir (Rukobia®)  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment IBA Ibalizumab-uiyk (Trogarzo®) is unlikely to be required MVC Maraviroc (Celsentri®, Selzentry®) ◆ No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. www.hiv-druginteractions.org

Interactions with Entry and Attachment Inhibitors Charts revised March 2021. Full information available at www.hiv-druginteractions.org Page 5 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ABT FTR IBA MVC ABT FTR IBA MVC Illicit/Recreational Other Alcohol     Acamprosate     Amphetamine     Acetazolamide     Cannabis     Acitretin     Cocaine     Adrenaline (Epinephrine)     Ecstasy (MDMA)     Alendronic Acid     GHB (Gamma-hydroxybutyrate)     Alfuzosin     Heroin        LSD (Lysergic acid diethylamide)     Allopurinol      Mephedrone     Atomoxetine Methamphetamine     Atropine     Phencyclidine (PCP)     Baclofen     Poppers (Amyl nitrate)     Betahistine     Immune Modulators Biperiden     Hydroxyurea (Hydroxycarbamide)     Brimonidine     Interferon alpha     distribution. Cabergoline (lactation suppression)    

Interleukin 2 (Aldesleukin)     for Caffeine citrate     Peginterferon alfa-2a     Calcium folinate     Peginterferon alfa-2b     Cannabidiol (CBD)     Immunosuppressants Carbimazole     Adalimumab     Clomifene     Anti-thymocyte globulin     Colchicine     Azathioprine     Colestyramine (Cholestyramine)     Basiliximab     Cyproterone acetate     Belatacept     Denosumab     Ciclosporin        Mycophenolate     Disulfiram  Sirolimus     Dutasteride     Tacrolimus     Eltrombopag     Tocilizumab     Fampridine (Dalfampridine)     Lipid Lowering Agents Filgrastim     Alirocumab     Finasteride     Atorvastatin     Flibanserin     Bezafibrate     Glyceryl trinitrate (Nitroglycerin)     Clofibrate     Goserelin     Evolocumab     Ibandronic acid     Ezetimibe     Isotretinoin     Fenofibrate     Leuprorelin     Fish oils     Levothyroxine     Fluvastatin     Mannitol     Gemfibrozil         Lovastatin     Methylphenidate Pitavastatin     Modafinil     Pravastatin     Naftidrofuryl     Rosuvastatin     Naloxone     Simvastatin     Naltrexone     Overactive Bladder Agents Neostigmine     Darifenacin     Nicorandil     Fesoterodine     Orlistat     Mirabegron     Penicillamine     Oxybutynin     Pentoxifylline     Solifenacin     Pilocarpine     Tolterodine     Potassium     Trospium     Probenecid     Oxytocics Propylthiouracil     Ergometrine (Ergonovine)     Protamine sulphate     Mifepristone     Pyridostigmine     Misoprostol     Sevelamer     Oxytocin     Strontium ranelate     Parkinsonism Agents Sulfasalazine     Apomorphine     Tamsulosin     Benserazide         Cabergoline (Parkinson’s)     Thalidomide Carbidopa     Tranexamic acid     Levodopa     Triptorelin     Pramipexole     Ursodeoxycholic acid     Rasagiline     Varenicline     Ropinirole     Zoledronic acid     Steroids Beclometasone    

Betamethasone     Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Budesonide     Ciclesonide     Clobetasol     Dexamethasone     Fludrocortisone     Flunisolide     Fluocinolone     Fluticasone     Hydrocortisone (oral)     Hydrocortisone (topical)     Megestrol acetate     Methylprednisolone     Mometasone     Nandrolone     Oxandrolone     Prednisolone     Prednisone     Stanozolol     Testosterone     Triamcinolone    

Key to abbreviations Key to symbols ABT Albuvirtide (Aikening®) ⚫ These drugs should not be coadministered FTR Fostemsavir (Rukobia®)  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment IBA Ibalizumab-uiyk (Trogarzo®) is unlikely to be required MVC Maraviroc (Celsentri®, Selzentry®) ◆ No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.